CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:scRNA-seq reveals ATPIF1 activity in control of T cell antitumor activity.
scRNA-seq reveals ATPIF1 activity in control of T cell antitumor activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
ATP合酶抑制因子1(ATPIF1)是一种线粒体蛋白,可抑制F1Fo-ATP合酶;但ATPIF1在调控T细胞免疫活性中的作用尚不清楚。
本研究通过遗传学方法,在肿瘤模型中确定了ATPIF1对诱导CD8阳性T细胞功能的作用。在ATPIF1敲除小鼠中,ATPIF1基因失活损害CD8阳性T细胞的免疫功能,导致B16黑色素瘤和Lewis肺癌迅速生长。敲除小鼠来源的T细胞增殖和IFN-γ分泌能力下降;活化后,其代谢重编程表现为糖酵解增加、氧化磷酸化(OXPHOS)降低。单细胞RNA测序(scRNA-seq)显示,敲除小鼠肿瘤浸润白细胞(TIL)中的T细胞耗竭增加,流式细胞术进一步证实了这一结果。相反,T细胞中过表达ATPIF1可提高IFN-γ和颗粒酶B表达,增加CAR-T 细胞中的中央记忆T细胞亚群,并提升NALM-6荷瘤小鼠的生存率。这些数据表明,ATPIF1缺失可通过诱导T细胞耗竭造成肿瘤免疫缺陷,而ATPIF1过表达能够增强T细胞抗肿瘤免疫。
因此,ATPIF1是癌症免疫治疗中调节CD8阳性T细胞抗肿瘤免疫的潜在分子靶点;诱导ATPIF1活性可能增强CAR-T 细胞的治疗作用。
ATP synthase inhibitory factor 1 (ATPIF1) is a mitochondrial protein with an activity in inhibition of F 1 F o -ATP synthase. ATPIF1 activity remains unknown in the control of immune activity of T cells. In this study, we identified ATPIF1 activity in the induction of CD8 + T cell function in tumor models through genetic approaches. ATPIF1 gene inactivation impaired the immune activities of CD8 + T cells leading to quick tumor growth (B16 melanoma and Lewis lung cancer) in ATPIF1-KO mice. The KO T cells exhibited a reduced activity in proliferation and IFN- secretion with metabolic reprogramming of increased glycolysis and decreased oxidative phosphorylation (OXPHOS) after activation.
T cell exhaustion was increased in the tumor infiltrating leukocytes (TILs) of KO mice as revealed by the single-cell RNA sequencing (scRNA-seq) and confirmed by flow cytometry. In contrast, ATPIF1 overexpression in T cells increased expression of IFN- and Granzyme B, subset of central memory T cells in CAR-T cells, and survival rate of NALM-6 tumor-bearing mice. These data demonstrate that ATPIF1 deficiency led to tumor immune deficiency through induction of T cell exhaustion. ATPIF1 overexpression enhanced the T cell tumor immunity.
Therefore, ATPIF1 is a potential molecular target in the modulation of antitumor immunity of CD8 + T cells in cancer immunotherapy. Induction of ATPIF1 activity may promote CAR-T activity in cancer therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。